ライフサイエンスコーパス: IGRA

1 IGRA conversions occurred in 9% (n = 63 of 718), whereas

2 IGRA outcomes are highly heritable in various population

3 IGRA results should be interpreted cautiously when TB re

4 IGRAs are preferred over TST when specificity is paramou

5 IGRAs measure interferon gamma production by lymphocytes

6 IGRAs offer logistical advantages and are supposed to of

7 ectively reduced the tuberculosis risk among IGRA-positive contacts.

8 der of Summa Health Care, who has adopted an IGRA for M. tuberculosis detection in his laboratory, an

9 ors should be tested with either a TST or an IGRA.

10 uberculosis (TB) infection screening with an IGRA (QuantiFERON-TB Gold In-Tube; Cellestis, Carnegie,

11 LTBI prevalence was 52.7% and 61.2% (TST and IGRA respectively).

12 Agreement between the TST and IGRA results, measured by the kappa coefficient, was 0.2

13 er TST in IMIDs or to recommend both TST and IGRA to enhance sensitivity.

14 Both the TST and IGRAs are moderately sensitive and highly specific withi

15 is study compared the performance of TST and IGRAs in five different groups of immunocompromised pati

16 skin test (TST) and IFN-gamma release assay (IGRA) (QuantiFERON Gold).

17 fined by a positive IFN-gamma release assay (IGRA) result in the absence of active tuberculosis.

18 est (TST) or interferon gamma release assay (IGRA) results, normal examinations, and normal chest rad

19 Gold In-Tube interferon-gamma release assay (IGRA) testing at baseline and after 24 months in a low t

20 an "in-tube" gamma interferon release assay (IGRA) using TB-specific antigens in comparison to the TS

21 IFN-gamma release assay (IGRA) was combined with a flow cytometric assay that det

22 IFN-gamma release assays (IGRAs) are alternatives to tuberculin skin testing (TST)

23 Interferon gamma release assays (IGRAs) are blood-based tests intended for diagnosis of l

24 Gamma interferon (IFN-gamma) release assays (IGRAs) are functional assays used serially to measure th

25 IFN-gamma release assays (IGRAs) are in vitro blood tests that measure T-cell rele

26 In vitro gamma interferon release assays (IGRAs) are increasingly used as an alternative to the tr

27 Although IFN-gamma release assays (IGRAs) are widely used to screen for Mycobacterium tuber

28 efulness of interferon gamma release assays (IGRAs) for active tuberculosis and mortality in Kenyan h

29 ic value of interferon-gamma release assays (IGRAs) for active tuberculosis in low- and middle-income

30 evidence on interferon-gamma release assays (IGRAs) for the diagnosis of latent tuberculosis infectio

31 New interferon-gamma release assays (IGRAs) offer improvements over TST, but these tests have

32 Interferon gamma (IFN-gamma) release assays (IGRAs) provide an in vitro measurement of antimycobacter

33 Interferon-gamma Release Assays (IGRAs) significantly increases the possibility for early

34 the use of interferon gamma release assays (IGRAs) to detect Mycobacterium tuberculosis.

35 nterferon (gamma interferon) release assays (IGRAs) with known markers of tuberculosis (TB) treatment

36 TST and two interferon-gamma release assays (IGRAs): T-SPOT.TB (Oxford Immunotec, Oxford, UK) and Qua

37 e and T-SPOT.TB, the two currently available IGRAs, in immunocompromised adults, including persons in

38 )), were calculated for associations between IGRA positivity and risk of active tuberculosis and mort

39 Agreement between IGRAs was fair (kappa=0.71).

40 oled specificity estimates were low for both IGRA platforms among all participants (T-SPOT, 61% [95%

41 he index of suspicion for LTBI is high, both IGRA and TST could be performed, especially prior to ini

42 that in the face of immune-suppression, both IGRA and TST can be falsely negative and are thus only d

43 oled analysis, 2,282 patients underwent both IGRA and TST screening prior to golimumab treatment.

44 Sensitivity of both IGRAs for detection of risk factors for LTBI was 33.3% (

45 ity for early diagnosis of tuberculosis, but IGRAs alone cannot discriminate active TB from LTBI.

46 a rate of positivity of 9.1% (71 of 781) by IGRA (P=0.0002).

47 (62 of 1,248) and the rate of positivity by IGRA was 5.8% (72 of 1,248) (P=0.3745).

48 esults by TST, 7.0% with positive results by IGRA, and 2.6% with positive results on both tests.

49 Combining IGRAs did not significantly improve sensitivity.

50 the data that have been published concerning IGRA.

51 Adolescents with converted IGRA status (QFT converters [n = 534]) and randomly chos

52 On the basis of the available data, IGRAs have advantages over the tuberculin skin test in s

53 There was no consistent evidence that either IGRA was more sensitive than the tuberculin skin test fo

54 Only a few studies have evaluated IGRAs in IMIDs, and most were small and varied considera

55 ST at the 10-mm and 15-mm thresholds and for IGRAs ranged from 0.95 to 0.99 (34 studies; n = 23853).

56 1-0.87 [11 studies; n = 988]), and those for IGRAs ranged from 0.77 to 0.90 (57 studies; n = 4378).

57 Future IGRA research should focus on children aged less than 5

58 tified by pregnancy versus delivery, 20% had IGRA(+)/TST(-) discordance at each time point.

59 developed postpartum TB, of which three had IGRA(+)/TST(-) discordance during pregnancy.

60 However, IGRAs have biological limitations similar to TST and som

61 There was also a 19% increase in IGRA positivity risk for every additional year of school

62 3 women tested, 52 (15.6%) had indeterminate IGRA results.

63 nificantly more likely to have indeterminate IGRA results and produced quantitatively less gamma inte

64 lly indeterminate, the rate of indeterminate IGRA findings for latent TB was much lower than has been

65 ve TB and probable LTBI in RTRs is very low, IGRAs cannot be used to exclude LTBI.

66 We performed multiple IGRA tests using leftover stimulated plasma according to

67 A baseline positive TST with negative IGRAs was associated with bacillus Calmette-Guerin (BCG)

68 However, studies have shown nonreproducible IGRA results.

69 ntries, neither the tuberculin skin test nor IGRAs have value for active tuberculosis diagnosis in ad

70 conducted a genome-wide linkage analysis of IGRA phenotypes in families from a tuberculosis househol

71 TB infection, results of this comparison of IGRA and TST in a large cohort of patients with rheumati

72 with a CD4>200 had a two-fold higher risk of IGRA positivity compared to those with CD4 counts <200 (

73 rt the novel findings of a decreased risk of IGRA positivity in HIV-infected smokers possibly due to

74 A decreased risk of IGRA positivity was observed in persons with a BCG scar

75 Although the clinical significance of IGRA conversions and reversions remains to be establishe

76 ecommendations on how to minimize sources of IGRA variability.

77 Determine the performance characteristics of IGRAs versus TST for serial testing of HCWs.

78 These results emphasize the limitations of IGRAs in the setting of chronic immunosuppressive therap

79 all, the findings demonstrate performance of IGRAs equivalent or superior to that of the TST.

80 nocentric studies have evaluated the role of IGRAs to predict the development of tuberculosis in rece

81 Current evidence supports usage of IGRAs in children aged 5 years or older.

82 to more accurately define the usefulness of IGRAs in immunocompromised patients.

83 es have been done on the predictive value of IGRAs in IMID patients.

84 Although the negative predictive value of IGRAs is high, the risk for the development of tuberculo

85 analysis of the strengths and weaknesses of IGRAs.

86 edications and the impact of type of IMID on IGRA performance.

87 n sources of variability and their impact on IGRA results.

88 The rate of indeterminate results for TB on IGRA was 1.8%.

89 dividuals and was poorly predicted by TST or IGRAs.

90 The combined sensitivities of the TST plus IGRA and TST plus a single sputum smear were 96% and 93%

91 Positive IGRA results for HIV-1-infected pregnant women were asso

92 252 enrolled, 71 (28%) women had a positive IGRA but only 27 (10%) had a positive TST (P < 0.005).

93 In those with a positive IGRA result, tuberculosis incidence was 0.2 (QFT) and 0

94 A positive IGRA was associated with known TB contact (odds ratio, 3

95 during follow-up, 5 had concordant positive IGRA results and 2 were IGRA converters.

96 th positive TST findings, 27.4% had positive IGRA findings.

97 emaining 281 women, 120 (42.7%) had positive IGRA results, which were associated with a 4.5-fold incr

98 n (CD4 cell count, <250 cells/muL), positive IGRA results were associated with increased risk of mate

99 Among the patients with positive IGRA findings, 36.9% had positive TST findings.

100 increasing tendency for guidelines to prefer IGRA over TST in IMIDs or to recommend both TST and IGRA

101 disease, but the risk associated with recent IGRA conversions is unknown.

102 Evidence regarding IGRA performance in children is accumulating rapidly.

103 versions remains to be established, repeated IGRA testing seems to be of value in HIV-1-infected indi

104 Limited data suggest IGRAs may not perform well for serial testing of healthc

105 ycobacterium tuberculosis-specific T-SPOT.TB IGRA positivity were determined during pregnancy in a hi

106 rrent evidence does not clearly suggest that IGRAs are better than tuberculin skin test (TST) in iden

107 The IGRA used to screen for latent TB was the QuantiFERON-TB

108 m and additional cytokines measured from the IGRA supernatant.

109 in all TB cases was higher than that of the IGRA (90% versus 76%, respectively).

110 The sensitivity of the IGRA for TB was considered a surrogate of sensitivity in

111 cterium tuberculosis, the sensitivity of the IGRA for the diagnosis of TB varied by clinical subgroup

112 The sensitivity of the IGRA in human immunodeficiency virus (HIV)-infected TB c

113 nts with rheumatic diseases suggest that the IGRA provides greater specificity and possibly greater s

114 When the IGRA was repeated in patients whose results were initial

115 concordant positive IGRA results and 2 were IGRA converters.

116 substantial variability in TB response when IGRAs are repeated using the same patient sample.

117 ions occurred in 9% (n = 63 of 718), whereas IGRA reversions were seen in 33% (n = 25 of 76) of indiv

118 534]) and randomly chosen adolescents whose IGRA status had remained negative over a period of 2 yea

119 The TST combined with IGRA or with a single sputum smear may have a role in ex

120 Compared with IGRA(+)/TST(+), women with IGRA(+)/TST(-) discordance ha

121 Patients with IGRA(+) CD4(+)CD25(+)CD134(+) T-cell phenotypes had the

122 Pregnant women with IGRA(+)/TST(-) discordance had less IFN-gamma and IL-2 t

123 Compared with IGRA(+)/TST(+), women with IGRA(+)/TST(-) discordance had significantly less IFN-ga

124 Our results reveal that in combination with IGRAs, CD161-based indices provide a novel, fast diagnos

125 urred six to nine times more frequently with IGRAs than TST; repeat testing of apparent converters is

126 revealed higher false conversion rates with IGRAs than with TST.

127 Clinicians could consider starting with IGRAs in individuals with a history of Bacille Calmette-